Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | LGMN | Q99538 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3758794 | 0.82 | LPL (0.40) | KDM4ELGMNMAPK1MEN1USP2 | |
| SCHEMBL1660361 | 0.81 | LPL (0.40) | MAPK1 | |
| SCHEMBL22290797 | 0.81 | TSHR (0.33) | ALDH1A1MAPTHSD17B10 | |
| SCHEMBL22290795 | 0.81 | TSHR (0.33) | ALDH1A1MAPTHSD17B10 | |
| SCHEMBL29925545 | 0.80 | KDM4E (0.39) | KDM4ELGMNMAPK1MEN1USP2 | |
| SCHEMBL27032333 | 0.80 | KDM4E (0.39) | KDM4ELGMNMAPK1MEN1USP2 | |
| SCHEMBL3758875 | 0.76 | KDM4E (0.38) | KDM4EMAPK1MEN1ALDH1A1MAPT | |
| SCHEMBL31125907 | 0.76 | KDM4E (0.38) | KDM4EMAPK1MEN1ALDH1A1MAPT | |
| SCHEMBL2037550 | 0.75 | MAPT (0.44) | MAPK1MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL10209954 | 0.75 | KMO (0.50) | KDM4EMEN1ALDH1A1TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197895-B1 | NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF FIBROTIC DISEASES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-03-11 | — | — | EP | disclosed |
| US-10004724-B2 | Compounds alpha v beta 6 integrin antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-26 | — | — | US | disclosed |
| US-20170290818-A1 | NOVEL COMPOUNDS ALPHA v BETA 6 INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| EP-3197895-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016046241-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10004724-B2 | Compounds alpha v beta 6 integrin antagonists | ITGAV, ITGB6, ITGB1 | KDM4E 1943/4885PIK3C3 3168/4885CYP3A4 1917/4885 |
| US-20170290818-A1 | NOVEL COMPOUNDS ALPHA v BETA 6 INTEGRIN ANTAGONISTS | ITGAV, ITGB6, ITGB1 | KDM4E 2115/4885PIK3C3 3311/4885CYP3A4 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.